Proposed AI ethics rules will require ethical committees in institutions; Japanese brand Muji’s two-decades old trademark dispute ends in defeat; and China steps up Belt and Road investment as Western trade barriers rise.
The first commercial AI application case in Zhejiang province defines legal limits on generative tools; CFIUS blocked more transactions last year than in previous years amid rising China tensions; and Fintech companies rush to raise equity for stablecoin activity in Hong Kong.
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
Hainan launches pilot program expanding financial products access to foreigners; Chinese companies reconsider pivot to Southeast Asia as region targeted by U.S. tariffs; and Chinese regulator puts U.S. outbound investments on hold.
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
The CSRC has not approved U.S. IPOs since April despite a small-cap listing rebound earlier; New arbitration rules emphasize party consent, tribunal independence, and risk management in AI use; and Record-high investments in Belt and Road Initiative driven by strategic sectors.
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
U.S. to tighten disclosure obligations of foreign listed companies, targeting China; China to allow local investors to invest more in overseas assets under QDII; and EU issues measures to restrict Chinese medical device manufacturers from accessing public procurement contracts
Western companies concerned about China's demand for sensitive rare earths information; Irish data regulators target transparency and transfer impact assessment failures in landmark decision; and China's largest insurer plans to raise HK$11.77 billion through convertible bond listing in Frankfurt
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
